Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity
about
Emerging and future therapies for hemophiliaEarly implementation of QbD in biopharmaceutical development: a practical exampleImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsClinical Pharmacology and Translational Aspects of Bispecific AntibodiesImmunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library ScreeningBalancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsFramework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsEntire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.Novel products for haemostasis - current status.Novel products for haemostasis.Clinical pharmacology of bispecific antibody constructs.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Emerging drugs for the treatment of hemophilia A and B.2017 Clinical trials update: Innovations in hemophilia therapy.Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.Production of recombinant coagulation factors: Are humans the best host cells?Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Current progress in innovative engineered antibodies.Precise quantification of mixtures of bispecific IgG produced in single host cells by liquid chromatography-Orbitrap high-resolution mass spectrometry.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.The making of bispecific antibodiesAnti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia AExpanding the Boundaries of Biotherapeutics with Bispecific AntibodiesADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q26781143-74CAC92A-BCA7-45CF-8B16-02E621792A1BQ26830466-4775E35F-3F1C-4AA1-9A1D-31DEBD90DBEAQ28072319-F1D18CF0-926D-4F83-B64D-6F4506C4A37CQ33648086-2D78A302-5ADD-45B1-9819-0F4E9195EC43Q33781380-D1027958-F6F1-4641-AB72-170F9C9DF49AQ34503723-B2521664-9AB9-42E9-9A4D-51FD1431AAC6Q35856534-CC5AEABD-1CC6-498F-B49C-5D69EC55186AQ35870955-3194D23C-9C6B-4DD4-A378-8999DB5045D9Q36214515-ED0AFFF2-72AB-471B-AE12-53DC9CB53B8CQ36215733-3A275285-B4D4-4B8F-849C-0855F88697F5Q36444225-9538C9DE-51C0-491E-805E-274410B40DD5Q37734869-9EDB8572-88F3-4904-9B60-205070F848C5Q38206849-19BF321D-5879-4978-9DBD-82CD6A4EFB3FQ38206850-DB77EE18-90A6-4496-AB07-0DB9A23F8D8EQ38364459-EE44B26F-628B-46E5-9DDE-7210495DDBE9Q38831148-E69BE10C-4E0F-4B6D-9B73-16BF0B39B6DBQ38861238-9F215439-A9F8-4046-8EB5-FE58990E6DF0Q38933707-72BBE63D-9A3B-4809-B02D-65EB4BEFA3E9Q38937725-4D751527-08EC-4DEC-BDF3-3DD9379036D8Q38951490-F1BDA359-C7FB-4682-8D8F-207B766810F6Q39170433-35FEDB68-3BC3-4F29-B61E-636A04EE124EQ39277950-A7CC116A-6663-460E-B12B-F3FBF5FEA66CQ40077818-EF8E2CE3-E536-43E6-82DC-E793BC1277AAQ41899683-5ACC5188-B42F-42F8-A82F-D2E8A9188684Q41953134-F6D5F683-014B-41AD-87ED-38031755D805Q42076342-1C1FD0FF-257B-4E0F-8079-20F95FD998C6Q42323236-7716E3C0-ECC7-4F52-AC16-4421A2F4B552Q45864199-D5C8F507-05D3-424A-B6E8-8E9952190D19Q45875541-7F21EF1B-8D52-4D2F-A3BC-9F1592641C13Q47696309-22C099AE-051D-4B25-BB4D-5A1E4ACCE8E3Q50124713-3CCED431-A3F0-4905-9483-15B65E1A907FQ50323216-33257A3A-EB6E-4FCE-BE6A-528187036CAFQ52744090-8493A86E-02CA-4432-9A13-720441ABACD4Q55211396-8B4F429A-12E9-44F7-9487-893EA4B2C300Q57816367-71B46737-330D-4804-A9C5-B2719677CE52Q58724935-37AB00E5-C07C-4EDA-B866-637C43CD82A8Q58869554-1854C4B3-5783-43FD-87A1-F0E16EA4B770
P2860
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Identification and multidimens ...... factor VIII cofactor activity
@ast
Identification and multidimens ...... factor VIII cofactor activity
@en
Identification and multidimens ...... factor VIII cofactor activity
@nl
type
label
Identification and multidimens ...... factor VIII cofactor activity
@ast
Identification and multidimens ...... factor VIII cofactor activity
@en
Identification and multidimens ...... factor VIII cofactor activity
@nl
prefLabel
Identification and multidimens ...... factor VIII cofactor activity
@ast
Identification and multidimens ...... factor VIII cofactor activity
@en
Identification and multidimens ...... factor VIII cofactor activity
@nl
P2093
P2860
P3181
P1433
P1476
Identification and multidimens ...... factor VIII cofactor activity
@en
P2093
Atsushi Muto
Aya Harada
Chifumi Moriyama
Eriko Tanaka
Kazutaka Yoshihashi
Keiko Esaki
Kunihiro Hattori
Miho Funaki
Sachiyo Suzuki
Takehisa Kitazawa
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0057479
P407
P577
2013-02-28T00:00:00Z